These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17153140)

  • 1. Fragment screening: an introduction.
    Leach AR; Hann MM; Burrows JN; Griffen EJ
    Mol Biosyst; 2006 Sep; 2(9):430-46. PubMed ID: 17153140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.
    Albert JS; Blomberg N; Breeze AL; Brown AJ; Burrows JN; Edwards PD; Folmer RH; Geschwindner S; Griffen EJ; Kenny PW; Nowak T; Olsson LL; Sanganee H; Shapiro AB
    Curr Top Med Chem; 2007; 7(16):1600-29. PubMed ID: 17979771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based drug discovery: what has it achieved so far?
    Alex AA; Flocco MM
    Curr Top Med Chem; 2007; 7(16):1544-67. PubMed ID: 17979767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based drug design: computational & experimental state of the art.
    Hoffer L; Renaud JP; Horvath D
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):500-20. PubMed ID: 21521152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of small molecule libraries for NMR screening and other applications in drug discovery.
    Jacoby E; Davies J; Blommers MJ
    Curr Top Med Chem; 2003; 3(1):11-23. PubMed ID: 12570776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and combinatorial synthesis of a novel kinase-focused library using click chemistry-based fragment assembly.
    Irie T; Fujii I; Sawa M
    Bioorg Med Chem Lett; 2012 Jan; 22(1):591-6. PubMed ID: 22104147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.
    Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS
    Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
    Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
    Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fragment-based drug discovery: concept and aim].
    Tanaka D
    Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.